D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)-

Request For Quotation
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Suppliers list
Company Name: Suzhou Meishi Biotechnology Co., Ltd.  
Tel: 1173954148q
Email: meishipharma@126.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- manufacturers

  • YM543 free base
  • YM543 free base pictures
  • $3100.00
  • 2026-08-15
  • CAS:655237-16-4
  • Purity:
  • Supply Ability: 10g
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Basic information
Product Name:D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)-
Synonyms:D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)-;YM543 free base
CAS:655237-16-4
MF:C23H24O6
MW:396.44
EINECS:
Product Categories:
Mol File:655237-16-4.mol
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Structure
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Chemical Properties
Boiling point 625.3±55.0 °C(Predicted)
density 1.400±0.06 g/cm3(Predicted)
pka14.48±0.10(Predicted)
Safety Information
MSDS Information
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Usage And Synthesis
UsesYM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes[1][2].
in vivo

YM543 free base (0-3 mg/kg; p.o.) reduces blood glucose levels and improved glucose tolerance with a concomitant increase in urinary glucose excretion in KK/Ay 2 diabetic mice, effects that were sustained even after 12 h[1].

Animal Model:KK/Ay 2 diabetic mice[1]
Dosage:0.1, 0.3, 1, and 3 mg/kg
Administration:oral administration
Result:Had a strong and sustained antihyperglycemic effect in both KK/Ay type 2 diabetic mice.
Animal Model:Male Sprague–Dawley rats[1]
Dosage:1.0 and 3.0 mg/kg
Administration:intravenous injection (1.0 mg/kg) and oral administration (3.0 mg/kg)
Result:1.19
Administrationiv (1 mg/kg)po (3 mg/kg)
T1/2 (h)0.91.3
CLtot (L/h/kg)2483
Vdss (L/kg)3360
Cmax (ng/mL)101
Tmax (h)0.5
AUC0-inf (ng h/mL)403
F %29
IC 50SGLT2
References[1] Ikegai K, et, al. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543. Bioorg Med Chem. 2013 Jul 1;21(13):3934-48. DOI:10.1016/j.bmc.2013.03.067
[2] Nakada N. Evaluation of the Utility of Chimeric Mice with Humanized Livers for the Characterization and Profiling of the Metabolites of a Selective Inhibitor (YM543) of the Sodium-Glucose Cotransporter 2. Pharm Res. 2017 Apr;34(4):874-886. DOI:10.1007/s11095-017-2116-4
D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)- Preparation Products And Raw materials
Tag:D-Glucitol, 1,5-anhydro-1-C-[5-(2-azulenylmethyl)-2-hydroxyphenyl]-, (1S)-(655237-16-4) Related Product Information
LEUCOPELARGONIDIN Tenuiphenone B 3,4,4',7-Tetrahydroxyflavan (S)-(2-methoxyphenyl)((tetrahydro-2H-pyran-4-yl)oxy)methanol 1,3-Propanedione, 1-(3-α-L-arabinopyranosyl-5-β-D-glucopyranosyl-2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)- 2-Tetrahydro-2-furanylphenol